Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Share-based Compensation (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed Share-based Compensation for 11 consecutive years, with $4.7 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation changed N/A to $4.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.4 million through Dec 2025, changed N/A year-over-year, with the annual reading at $13.3 million for FY2025, 183.13% up from the prior year.
  • Share-based Compensation for Q4 2025 was $4.7 million at Crescent Biopharma, up from $405428.0 in the prior quarter.
  • The five-year high for Share-based Compensation was $4.7 million in Q4 2025, with the low at $36000.0 in Q1 2024.
  • Average Share-based Compensation over 5 years is $1.2 million, with a median of $913979.0 recorded in 2022.
  • The sharpest move saw Share-based Compensation crashed 95.86% in 2024, then soared 1026.19% in 2025.
  • Over 5 years, Share-based Compensation stood at $1.3 million in 2021, then plummeted by 31.88% to $899201.0 in 2022, then grew by 1.02% to $908371.0 in 2023, then tumbled by 92.4% to $69000.0 in 2024, then surged by 6776.81% to $4.7 million in 2025.
  • According to Business Quant data, Share-based Compensation over the past three periods came in at $4.7 million, $405428.0, and $69000.0 for Q4 2025, Q1 2025, and Q3 2024 respectively.